JP3023962B2 - Antiallergic agent - Google Patents
Antiallergic agentInfo
- Publication number
- JP3023962B2 JP3023962B2 JP1294253A JP29425389A JP3023962B2 JP 3023962 B2 JP3023962 B2 JP 3023962B2 JP 1294253 A JP1294253 A JP 1294253A JP 29425389 A JP29425389 A JP 29425389A JP 3023962 B2 JP3023962 B2 JP 3023962B2
- Authority
- JP
- Japan
- Prior art keywords
- epigallocatechin gallate
- antiallergic agent
- agent
- tea
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【発明の詳細な説明】 （産業上の利用分野） 本発明は、抗アレルギー剤に関する。Description: TECHNICAL FIELD The present invention relates to an antiallergic agent.
（従来の技術） アレルギー反応は、抗原抗体反応により組織に障害を
与える現象で、その発症メカニズムによってＩ型（即時
型）からIV型（遅延型）の４種に分類されている。この
うちＩ型アレルギーは、抗原によりIgE感作肥満細胞が
特異的に刺激され、化学伝達物質が遊離され炎症を引き
起こすとされている。(Prior Art) Allergic reactions are phenomena that damage tissues by antigen-antibody reactions, and are classified into four types from type I (immediate type) to type IV (delayed type) according to their onset mechanism. Among them, type I allergy is said to specifically stimulate IgE-sensitized mast cells by antigens, release chemical messengers, and cause inflammation.
タンニン類の抗アレルギー剤としての利用は、特開昭
59−196884号で新規なるタンニンと称されるTeasinensi
n A,Teasinensin Bまたは次の一般式で表されるタンニ
ンが示されている。The use of tannins as antiallergic agents is disclosed in
Teasinensi called new tannin in 59-199684
nA, Teasinensin B or a tannin represented by the following general formula is shown.
一般式 （発明が解決しようとする課題） しかしながら、上記新規なるタンニンは非常に単離精
製が困難であり収率も低い、たとえばTeasinensin Aは
新鮮茶葉からの収率が0.00049％、Teasinensin Bは0.00
013％と記されているように非常に収率が低く実用化は
困難である。General formula (Problems to be Solved by the Invention) However, the novel tannin is very difficult to isolate and purify and has a low yield. For example, the yield from fresh tea leaves of Teasinensin A is 0.00049%, and the yield of Teasinensin B is 0.00
As described as 013%, the yield is extremely low and practical application is difficult.
本発明者は、茶カテキン類には、強力な抗酸化力、血
中コレステロール抑制、血圧降下、抗菌、抗ガン、消臭
などの機能、用途があることが知られていることに着目
し、この点から前記課題を解決すべく研究したものであ
り、Ｉ型アレルギーに対する治療薬を開発する一つの方
法である肥満細胞からのヒスタミン遊離抑制活性を指標
に、茶カテキンの活性の研究を行った。その結果、茶カ
テキン、特にエピガロカテキンガレートが強い抑制効果
を示すことを見出し、抗アレルギー剤としての本発明を
なすに至ったものである。The present inventors have noted that tea catechins are known to have strong antioxidant power, blood cholesterol suppression, blood pressure lowering, antibacterial, anticancer, deodorant and other functions and uses, In view of this, it was studied to solve the above-mentioned problem, and the activity of tea catechin was studied using the activity of inhibiting histamine release from mast cells as an index, which is one method of developing a therapeutic agent for type I allergy. . As a result, they found that tea catechins, particularly epigallocatechin gallate, exhibited a strong inhibitory effect, which led to the present invention as an antiallergic agent.
（課題を解決するための手段） 上記課題を解決するために、本発明は、茶葉を含む茶
から単離精製したエピガロカテキンガレートを主成分と
して抗アレルギー剤としたことを特徴とする。(Means for Solving the Problems) To solve the above problems, the present invention is characterized in that epigallocatechin gallate isolated and purified from tea including tea leaves is used as an antiallergic agent as a main component.
該エピガロカテキンガレートは次の構造式で表される
ものである。The epigallocatechin gallate is represented by the following structural formula.
茶葉中には10〜15％のカテキンが含まれ、その約60％
がエピガロカテキンガレートである。エピガロカテキン
ガレートは茶葉中に特異的に含まれ、その分離精製技術
はすでに確立されており、エピガロカテキンガレートを
茶葉から数％例えば約５％の収率で得ることが可能であ
る。 Tea leaves contain 10-15% catechins, about 60% of which
Is epigallocatechin gallate. Epigallocatechin gallate is specifically contained in tea leaves, and its separation and purification techniques have already been established. Epigallocatechin gallate can be obtained from tea leaves in a yield of several%, for example, about 5%.
（作用） 本発明剤の抗アレルギー活性は現行市販の抗アレルギ
ー剤であるトラニラストの約10倍であることが確認され
た。(Action) It was confirmed that the antiallergic activity of the agent of the present invention was about 10 times that of the current commercially available antiallergic agent tranilast.
（実施例） カラムクロマトグラフィー等の公知の方法（例えば、
特開平１−175978号に開示の方法）により単離精製した
エピガロカテキンガレートを用い下記の方法で試験し
た。(Example) A known method such as column chromatography (for example,
Epigallocatechin gallate isolated and purified according to the method disclosed in JP-A-1-175978) was tested by the following method.
脱血致死させたWistar系雄性ラットの腹腔内にTyrode
液を注入し、公知の方法により肥満細胞を単離し、106
個/mとなるようにPBSに懸濁し、細胞浮遊液を調製し
た。エピガロカテキンガレートを各濃度に調製した試料
溶液に上記細胞浮遊液を加えて37℃10分間放置した後、
脱顆粒誘発剤（シグマケミカルカンパニー製商品名「コ
ンパウンド48/80」を使用）を加え37℃、５分間反応さ
せた。その後氷冷したPBSを加え反応を停止し、遠心分
離（1000×ｇ、５分間）した上清中に遊離されたヒスタ
ミン量を高速液体クロマトグラフィーにより測定した。
なお、脱顆粒誘発剤の濃度は10μg/mとし、ヒスタミ
ン遊離抑制活性は、次の式により算出した（単位はいず
れもp mol）。Intraperitoneal Tyrode of Wistar male rats killed by exsanguination
Liquid is injected, the mast cells were isolated by a known method, 106
The cells were suspended in PBS at a concentration of cells / m to prepare a cell suspension. After adding the above cell suspension to the sample solution prepared at each concentration of epigallocatechin gallate and allowed to stand at 37 ° C for 10 minutes,
A degranulation-inducing agent (using "Compound 48/80" manufactured by Sigma Chemical Company) was added, and the mixture was reacted at 37 ° C for 5 minutes. Thereafter, ice-cooled PBS was added to stop the reaction, and the amount of histamine released in the supernatant subjected to centrifugation (1000 × g, 5 minutes) was measured by high performance liquid chromatography.
The concentration of the degranulation-inducing agent was set to 10 μg / m, and the histamine release inhibitory activity was calculated by the following equation (unit: pmol).
〔１−（Ｓ−Ｃ）／（Ｒ−Ｃ）〕×100 C;無処置細胞（試料も刺激剤も加えない細胞） R;刺激剤だけを加えた細胞から遊離されるヒスタミン量 S;試料と刺激剤を加えた細胞から遊離されるヒスタミン
量 上記の方法でエピガロカテキンガレートのヒスタミン
遊離抑制活性を分析した結果を、表１及び図面に示し
た。[1- (SC) / (RC)] × 100 C; untreated cells (cells to which neither sample nor stimulant was added) R; amount of histamine released from cells to which only stimulant was added S; sample And the amount of histamine released from cells to which the stimulant was added. The results of analyzing the histamine release inhibitory activity of epigallocatechin gallate by the above method are shown in Table 1 and the drawings.
表１に示したように、エピガロカテキンガレートは0.
5mg/mで78.9％±6.8のヒスタミン遊離抑制作用があ
り、0.10mg/mで61.4±2.5の抑制作用がある。1.0mg/m
で約60％のヒスタミン遊離抑制作用を持つ公知の抗ア
レルギー剤であるトラニラストの約10倍のヒスタミン遊
離抑制作用を持つという結果が得られた。従ってエピガ
ロカテキンガレート濃度が約0.1mg/mより濃い濃度に
おいて従来以上の効果が奏せられることが判明した。 As shown in Table 1, epigallocatechin gallate was 0.1%.
5 mg / m has a histamine release inhibitory effect of 78.9% ± 6.8, and 0.10 mg / m has an inhibitory effect of 61.4 ± 2.5. 1.0mg / m
As a result, a histamine release inhibitory action about 10 times that of tranilast, a known antiallergic agent having about 60% histamine release inhibitory action, was obtained. Therefore, it was found that the effect more than the conventional effect can be obtained when the epigallocatechin gallate concentration is higher than about 0.1 mg / m.
（発明の効果） 本発明によれば、入手容易な茶乃至茶葉を原料とし、
既に確立された簡便な単離精製技術を利用して製造容易
なエピガロカテキンガレートを用いることによって、例
えば公知の抗アレルギー剤であるトラニラストの約10倍
の強い効果を奏する抗アレルギー剤を提供することが可
能となる。この成分は自然植物から得られ、日常常用し
ているものであるので、合成物等に比して安全性が高い
という利点も有している。(Effects of the Invention) According to the present invention, easily available tea or tea leaves are used as raw materials,
By using epigallocatechin gallate, which is easy to produce using a simple isolation and purification technique that has already been established, it is possible to provide an anti-allergic agent that exhibits about 10 times stronger effect than, for example, tranilast, which is a known anti-allergic agent It becomes possible. Since this component is obtained from natural plants and is commonly used on a daily basis, it also has an advantage that its safety is higher than that of synthetic products.
図面は本発明に係る抗アレルギー剤のエピガロカテキン
ガレートのヒスタミン遊離抑制作用を表すグラフであ
る。The drawing is a graph showing the histamine release inhibitory effect of epigallocatechin gallate, an antiallergic agent according to the present invention.
フロントページの続き (72)発明者 杉山 清 静岡県静岡市瀬名200―16大学公舎302 (72)発明者 横田 正實 静岡県静岡市瀬名200―16大学公舎104 (56)参考文献 特開 昭59−196884（ＪＰ，Ａ) 西独国公開3603227（ＤＥ，Ａ１) (58)調査した分野(Int.Cl.7，ＤＢ名) A61K 31/35 A61K 31/78 C07D 311/62 ＣＡ（ＳＴＮ)Continuation of the front page (72) Inventor Kiyoshi Sugiyama 200-16 University Public Building, Sena 200-16 Shizuoka City, Shizuoka Prefecture 72 196884 (JP, A) Published in West Germany 3603227 (DE, A1) (58) Fields investigated (Int. Cl. 7 , DB name) A61K 31/35 A61K 31/78 C07D 311/62 CA (STN)
Claims (1)
ートを主成分とする抗アレルギー剤。An antiallergic agent comprising epigallocatechin gallate isolated and purified from tea as a main component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1294253A JP3023962B2 (en) | 1989-11-13 | 1989-11-13 | Antiallergic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1294253A JP3023962B2 (en) | 1989-11-13 | 1989-11-13 | Antiallergic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03157330A JPH03157330A (en) | 1991-07-05 |
| JP3023962B2 true JP3023962B2 (en) | 2000-03-21 |
Family
ID=17805330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1294253A Expired - Lifetime JP3023962B2 (en) | 1989-11-13 | 1989-11-13 | Antiallergic agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3023962B2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1157693A1 (en) * | 2000-05-12 | 2001-11-28 | National Agricultural Research Organisation (NARO) | Use of epigallocatechin 3-o-(3-o-methyl) gallate and/or epigallocatechin 3-o-(4-o-methyl) gallate for the treatment of allergy and/or inflammation |
| JP4549009B2 (en) * | 2002-07-03 | 2010-09-22 | サントリーホールディングス株式会社 | Novel derivative of flavone C-glycoside and composition containing the same |
| JP2005060277A (en) * | 2003-08-08 | 2005-03-10 | National Agriculture & Bio-Oriented Research Organization | Pollen allergy inhibiting tea leaves, tea bags and pollen allergy inhibiting compositions |
| JP2005289888A (en) | 2004-03-31 | 2005-10-20 | Suntory Ltd | Preparation method of flavone c glycoside derivative |
| JP4788994B2 (en) * | 2005-01-26 | 2011-10-05 | 独立行政法人農業・食品産業技術総合研究機構 | Functional food and drink |
| JP2007145830A (en) * | 2005-11-04 | 2007-06-14 | Kao Corp | Sneezing attack, rhinorrhea improving agent |
| JP5149494B2 (en) * | 2006-07-21 | 2013-02-20 | 株式会社 日本薬用食品研究所 | Ingredients of cha or assamcha and their uses |
| WO2016013654A1 (en) * | 2014-07-24 | 2016-01-28 | 株式会社プロテクティア | Allergen activity inhibitor and use thereof |
| JP7350304B2 (en) * | 2019-10-18 | 2023-09-26 | 国立大学法人徳島大学 | Allergic rhinitis symptom suppressant |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3603227A1 (en) | 1986-02-03 | 1987-08-20 | Andreas Dipl Chem Ing D Vincze | Pharmaceutical composition containing as active substance a mixture of (+)-catechin and ascorbolysinate |
-
1989
- 1989-11-13 JP JP1294253A patent/JP3023962B2/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3603227A1 (en) | 1986-02-03 | 1987-08-20 | Andreas Dipl Chem Ing D Vincze | Pharmaceutical composition containing as active substance a mixture of (+)-catechin and ascorbolysinate |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03157330A (en) | 1991-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3023962B2 (en) | Antiallergic agent | |
| US8852655B2 (en) | Anti-inflammatory and antioxidant cosmetic composition containing green tea polysaccharide and tricholoma matsutake extract | |
| CN100413835C (en) | Compounds that inhibit HIV TAT transactivation | |
| JP3626727B2 (en) | A composition containing a phenol compound derived from mimosa | |
| KR101633519B1 (en) | Cosmetic or dermatological composition containing an orchid extract, and cosmetic care method using said composition | |
| CZ299652B6 (en) | Process for preparing an extract of ginkgo biloba leaves highly enriched with active principles | |
| DE60011997T2 (en) | SUBSTITUTED BENZO (1,2-b: 5,4-b ') DIPYRANE-4-AMINE AS CCR5 MODULATORS | |
| JP4994222B2 (en) | Platelet aggregation inhibitor | |
| AU2001297027B2 (en) | Use of buchu extracts for hypertension | |
| DE69701301T2 (en) | Substituted benzyl derivatives of polyalkylene polyamines and their use in cosmetic and pharmaceutical compositions | |
| AU2001297027A1 (en) | Use of buchu extracts for hypertension | |
| JPH03255033A (en) | Treating agent for trichophyton | |
| CN119837781A (en) | Plant-source halitosis-resistant mouthwash and preparation method and application thereof | |
| Miyake et al. | Inhibitory effect of olopatadine hydrochloride (KW-4679), a novel antiallergic drug, on peptide leukotriene release from human eosinophils | |
| KR102077430B1 (en) | Filter material for removing heavy metals and formaldehyde | |
| JP7198275B2 (en) | Composition for care of skin cell damage caused by fine dust containing plum blossom extract | |
| JP7125145B2 (en) | A composition that protects the skin from heavy metals and formaldehyde | |
| KR101337564B1 (en) | Cosmetic components comprised of the rubiadin having anti-allergy activity | |
| JP2920151B2 (en) | Antiallergic agent | |
| JP4071466B2 (en) | Novel orcinol derivatives | |
| EP3110461A1 (en) | Fractions of extracts of helichrysum having mucohadesive properties | |
| US5871755A (en) | Dehydroalanine derivatives for protecting the skin, the mucous membranes and/or the hair from oxidative stress, cosmetic or dermatological compositions containing them | |
| JPS63238014A (en) | Composition for oral cavity application | |
| JP4190216B2 (en) | UV-induced mutation inhibitor and skin external preparation for UV-induced mutation suppression | |
| Rohrbach et al. | Cotton condensed tannin: a potent modulator of alveolar macrophage host-defense function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090121 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100121 Year of fee payment: 10 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100121 Year of fee payment: 10 |